Eupraxia Pharmaceuticals (NASDAQ:EPRX) Announces Earnings Results, Misses Estimates By $0.21 EPS

19 Mar 2026, 13:20 by Sarita Garza · The Markets Daily

Eupraxia Pharmaceuticals (NASDAQ:EPRX – Get Free Report) announced its earnings results on Thursday. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.21), Zacks reports.

Eupraxia Pharmaceuticals Stock Down 0.9%

Shares of NASDAQ EPRX opened at $7.51 on Thursday. The firm has a market cap of $270.06 million, a PE ratio of -7.29 and a beta of 1.27. The company’s fifty day simple moving average is $8.30 and its 200 day simple moving average is $6.87. Eupraxia Pharmaceuticals has a 12-month low of $2.68 and a 12-month high of $9.32.

Hedge Funds Weigh In On Eupraxia Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Vivo Capital LLC bought a new stake in Eupraxia Pharmaceuticals in the 3rd quarter valued at about $7,965,000. Ikarian Capital LLC bought a new position in Eupraxia Pharmaceuticals in the fourth quarter worth approximately $4,606,000. Squadron Capital Management LLC bought a new position in Eupraxia Pharmaceuticals in the fourth quarter worth approximately $3,775,000. Velan Capital Investment Management LP acquired a new stake in Eupraxia Pharmaceuticals in the third quarter valued at approximately $2,077,000. Finally, Royal Bank of Canada grew its stake in Eupraxia Pharmaceuticals by 21.1% in the first quarter. Royal Bank of Canada now owns 342,828 shares of the company’s stock valued at $1,125,000 after acquiring an additional 59,683 shares during the period.

Analyst Ratings Changes

EPRX has been the topic of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research report on Thursday, January 22nd. HC Wainwright dropped their price objective on Eupraxia Pharmaceuticals from $12.00 to $11.00 and set a “buy” rating on the stock in a research note on Tuesday. Cantor Fitzgerald upped their target price on Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the company an “overweight” rating in a research report on Thursday, January 15th. Zacks Research lowered Eupraxia Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Tuesday. Finally, Wall Street Zen cut Eupraxia Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, February 21st. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Eupraxia Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $15.00.

Get Our Latest Report on Eupraxia Pharmaceuticals

Key Stories Impacting Eupraxia Pharmaceuticals

Here are the key news stories impacting Eupraxia Pharmaceuticals this week:

Positive Sentiment: HC Wainwright retains a “Buy” rating with an $11.00 price target (reported as a lowered target from $12 but still showing sizable upside vs. the current price). Read More.
Positive Sentiment: Lifesci Capital maintains a “Strong‑Buy” stance on EPRX despite trimming FY2026 estimates — supportive for investor sentiment from a prominent life‑science shop. Read More.
Positive Sentiment: HC Wainwright projects FY2030 EPS of $0.17, indicating a path to eventual profitability that underpins longer‑term upside assumptions. Read More.
Neutral Sentiment: HC Wainwright issued updated quarterly estimates across 2026 (Q1–Q4) reflecting revised cadence of expected losses and recovery timing — these are informational for modeling but mixed in directional impact. Read More.
Negative Sentiment: Zacks Research downgraded EPRX from “Hold” to “Strong Sell”, a clear near‑term negative that can pressure sentiment and selling activity. Read More.
Negative Sentiment: HC Wainwright cut multiple forward EPS forecasts sharply (FY2026–FY2029 and several quarters), signaling weaker near‑term operating outlook and raising the bar for catalysts. Read More.
Negative Sentiment: Recent reported quarterly results (March 19) missed expectations (EPS of -$0.37 vs. consensus -$0.16), which likely triggered analyst revisions and the Zacks downgrade.

Eupraxia Pharmaceuticals Company Profile

(Get Free Report)

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.